Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.59 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.48 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.43 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10589560 | 0.84 | CYP4F2 (0.40) | CYP4F2CYP4A11TDP1 | |
| SCHEMBL4773216 | 0.84 | PPARA (0.48) | CYP4F2CYP4A11CYP4Z1TDP1ALOX5 | |
| SCHEMBL6286441 | 0.83 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL4774135 | 0.82 | ALDH1A1 (0.49) | — | |
| SCHEMBL8906499 | 0.82 | FFAR1 (0.50) | — | |
| SCHEMBL6288506 | 0.82 | CYP4F2 (0.70) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL68902 | 0.81 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL11437256 | 0.80 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL10206072 | 0.80 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL8907659 | 0.78 | KMT2A (0.36) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | CYP4F2 2166/4885CYP4A11 1191/4885CYP4Z1 3682/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | CYP4F2 2733/4885CYP4A11 2992/4885CYP4Z1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.